Company intelligence / Profile preview
New Epsilon Innovation Limited
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
New Epsilon Innovation Limited has at least one recombinant protein therapeutic candidate, Adargiminase, which is being evaluated in Phase 1 clinical trials for relapsing acute myeloid leukemia. No further details on results are available from public sources[7].
- Therapeutic areas
- Oncology
- Modalities
- Recombinant protein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on New Epsilon Innovation Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New Epsilon Innovation Limited.